Apr 24, 2019

Personalizing cancer therapies may combat resistance to targeted therapy drugs: Case reported in which mutation conferring resistance to next-generation ALK inhibitor restored sensitivity to crizotinib -- ScienceDaily

American physicians report the case of a patients whose lung cancer was re-sensitized to crizotinib, a first-generation targeted therapy drug, by a mutation conferring resistance to a more selective, next-generation ALK inhibitor.

Proceed to the page: http://linkis.com/NlD6t

Similar Articles Added Earlier

Similar Articles Added Today

Most Recent sciencedaily.com Articles

Latest Links Processed